<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34936539</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8635</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Autophagy</Title><ISOAbbreviation>Autophagy</ISOAbbreviation></Journal><ArticleTitle>SQSTM1-mediated clearance of cytoplasmic mutant TARDBP/TDP-43 in the monkey brain.</ArticleTitle><Pagination><StartPage>1955</StartPage><EndPage>1968</EndPage><MedlinePgn>1955-1968</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2021.2013653</ELocationID><Abstract><AbstractText>The cytoplasmic accumulation and aggregates of TARDBP/TDP-43 (TAR DNA binding protein) are a pathological hallmark in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. We previously reported that the primate specific cleavage of TARDBP accounts for its cytoplasmic mislocalization in the primate brains, prompting us to further investigate how the cytoplasmic TARDBP mediates neuropathology. Here we reported that cytoplasmic mutant TARDBP reduced SQSTM1 expression selectively in the monkey brain, when compared with the mouse brain, by inducing <i>SQSTM1</i> mRNA instability via its binding to the unique 3'UTR sequence (GU/UG)n of the primate <i>SQSTM1</i> transcript. Overexpression of SQSTM1 could diminish the cytoplasmic C-terminal TARDBP accumulation in the monkey brain by augmenting macroautophagy/autophagy activity. Our findings provide additional clues for the pathogenesis of cytoplasmic TARDBP and a potential therapy for mutant TARDBP-mediated neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Dazhang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Fuyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Longhong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Laiqiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiangyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Jianmeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangdong Landao Biotechnology Co. Ltd, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, First Affiliated Hospital of Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, First Affiliated Hospital of Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shihua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Jiang</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hongkong-Macau Institute of Cns Regeneration, Jinan University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.16836643</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Autophagy</MedlineTA><NlmUniqueID>101265188</NlmUniqueID><ISSNLinking>1554-8627</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071456">Sequestosome-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101343">Sqstm1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071456" MajorTopicYN="N">Sequestosome-1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggregate</Keyword><Keyword MajorTopicYN="N">RNA instability</Keyword><Keyword MajorTopicYN="N">SQSTM1</Keyword><Keyword MajorTopicYN="N">TARDBP</Keyword><Keyword MajorTopicYN="N">non-human primate</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34936539</ArticleId><ArticleId IdType="pmc">PMC9466617</ArticleId><ArticleId IdType="doi">10.1080/15548627.2021.2013653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Lee VM, Trojanowski JQ, et al. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892118</ArticleId><ArticleId IdType="pubmed">20234357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VM, Trojanowski JQ, et al. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011;17(11):659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Nonaka T, Masuda-Suzukake M, et al. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther. 2017;172:22&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916654</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127(6):811&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, et al. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2016;27(4):472&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail - An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280(45):37572&#x2013;37584.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash A, Kumar V, Banerjee A, et al. Structural heterogeneity in RNA recognition motif 2 (RRM2) of TAR DNA-binding protein 43 (TDP-43): clue to amyotrophic lateral sclerosis. J Biomol Struct Dyn. 2020;39(1):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">31914861</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9(2):1104&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW.. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136(6):1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. Journal of Biological Chemistry. 2001;276(39):36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tank EM, Figueroa-Romero C, Hinder LM, et al. Abnormal RNA stability in amyotrophic lateral sclerosis. Nat Commun. 2018;9(1):2845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054632</ArticleId><ArticleId IdType="pubmed">30030424</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Onesto E, Megiorni F, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem. 2012;287(19):15635&#x2013;15647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346140</ArticleId><ArticleId IdType="pubmed">22427648</ArticleId></ArticleIdList></Reference><Reference><Citation>Costessi L, Porro F, Iaconcig A, et al. TDP-43 regulates beta-adducin (Add2) transcript stability. RNA Biol. 2014;11(10):1280&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615836</ArticleId><ArticleId IdType="pubmed">25602706</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Volkening K, Hammond R, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35(2):320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481916</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K, Leystra-Lantz C, Yang W, et al. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009;1305:168&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">19815002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Wu LS, Chang HY, et al. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105(3):797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">18088371</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C, Wilke C, Simon-Sanchez J, et al. The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. Genet Med. 2018;20(2):240&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846812</ArticleId><ArticleId IdType="pubmed">28749476</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Lim J, Wang Q, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16(5):917&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144840</ArticleId><ArticleId IdType="pubmed">31362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Purtell K, Lachance V, et al. Autophagy receptors and neurodegenerative diseases. Trends Cell Biol. 2017;27(7):491&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">28169082</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha-Molstad H, Yu JE, Feng Z, et al. p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nat Commun. 2017;8(1):102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524641</ArticleId><ArticleId IdType="pubmed">28740232</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurin N, Brown JP, Morissette J, et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379146</ArticleId><ArticleId IdType="pubmed">11992264</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68(11):1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Rainero I, Chio A, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79(15):1556&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655323</ArticleId><ArticleId IdType="pubmed">22972638</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kovacs GG, et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 2014;128(3):397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131163</ArticleId><ArticleId IdType="pubmed">24899140</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Nonaka T, Hasegawa M, et al. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett. 2003;342(1&#x2013;2):41&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami I, Arai T, Hasegawa M, et al. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138(5):751&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800885</ArticleId><ArticleId IdType="pubmed">31555895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Rollinson S, Robinson A, et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2013;1(1):68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893586</ArticleId><ArticleId IdType="pubmed">24252525</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu JR, Geetha T, Wooten MW, et al. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem. 2005;94(1):192&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh Babu J, Lamar Seibenhener M, Peng J, et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem. 2008;06(1):107&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18346206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Mitsui S, Pan L, et al. Functional links between SQSTM1 and ALS2 in the pathogenesis of ALS: cumulative impact on the protection against mutant SOD1-mediated motor dysfunction in mice. Hum Mol Genet. 2016;25(15):3321&#x2013;3340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27439389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Odagiri S, Miki Y, et al. p62 deficiency enhances alpha-synuclein pathology in mice. Brain Pathol. 2015;25(5):552&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029467</ArticleId><ArticleId IdType="pubmed">25412696</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi H, Adachi H, Katsuno M, et al. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. J Neurosci. 2013;33(18):7710&#x2013;7727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618982</ArticleId><ArticleId IdType="pubmed">23637164</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Rademakers R, Petrucelli L, et al. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis. 2013;33(Suppl 1):S35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532959</ArticleId><ArticleId IdType="pubmed">22751173</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Tong J, Bi F, et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012;122(1):107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X, Chiang PM, Price DL, et al. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A. 2010;107(37):16325&#x2013;16330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Oiwa K, Murata Y, et al. ALS-linked TDP-43(M337V) knock-in mice exhibit splicing deregulation without neurodegeneration. Mol Brain. 2020;13(1). DOI:10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106(44):18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Wang CE, Wei W, et al. TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain. Hum Mol Genet. 2014;23(10):2678&#x2013;2693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990167</ArticleId><ArticleId IdType="pubmed">24381309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, Constable R, So E, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107(8):3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Yang H, Yan S, et al. Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain. Mol Neurodegener. 2015;10(1):42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557629</ArticleId><ArticleId IdType="pubmed">26334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Guo XY, Yang WL, et al. Caspase-4 mediates cytoplasmic accumulation of TDP-43 in the primate brains. Acta Neuropathol. 2019;137(6):919&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531422</ArticleId><ArticleId IdType="pubmed">30810811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Bai DZ, Zhu LH, et al. Cytoplasmic TDP-43 impairs the activity of the ubiquitin-proteasome system. Exp Neurol. 2021;345:113833.</Citation><ArticleIdList><ArticleId IdType="pubmed">34363810</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, Wu TH, Wu CY, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425(2):219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean M, Romano V, Pantoja-Uceda D, et al. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 2016;283(7):1242&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756435</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, Lim LZ, Wei Y, et al. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc Natl Acad Sci U S A. 2014;111(52):18619&#x2013;18624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="pubmed">25503365</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131(6):1149&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Attarwala IY, Xie XQ, et al. SQSTM1/p62: a potential target for neurodegenerative disease. ACS Chem Neurosci. 2019;10(5):2094&#x2013;2114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712989</ArticleId><ArticleId IdType="pubmed">30657305</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin WH, Park JH, Chung KC, et al. The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson&#x2019;s disease. BMB Rep. 2020;53(1):56&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999829</ArticleId><ArticleId IdType="pubmed">31818366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ, et al. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A, Sugai A, Kato T, et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44(12):5820&#x2013;5836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Bigio EH, Mishra M, et al. TARDBP 3&#x2b9;-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol. 2009;118(5):633&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783457</ArticleId><ArticleId IdType="pubmed">19618195</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida A, Sasaguri H, Kimura N, et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain. 2012;135(Pt 3):833&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286326</ArticleId><ArticleId IdType="pubmed">22252998</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Meng P, Zheng Y, et al. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116(2):248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Zhang HX, Mori F, et al. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res. 2012;90(10):2034&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">22674379</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Strom AL, Kilty R, et al. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem. 2007;282(15):11068&#x2013;11077.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatloukal K, Stumptner C, Fuchsbichler A, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol. 2002;160(1):255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867135</ArticleId><ArticleId IdType="pubmed">11786419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Phaneuf D, Cordeau P, et al. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD. Mol Neurodegener. 2021;16(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792109</ArticleId><ArticleId IdType="pubmed">33413517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormeno F, Hormazabal J, Moreno J, et al. Chaperone Mediated Autophagy Degrades TDP-43 Protein and Is Affected by TDP-43 Aggregation. Front Mol Neurosci. 2020;13:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7040037</ArticleId><ArticleId IdType="pubmed">32132902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LK, Lin W-L, Miriyala S, et al. p62 pathology model in the rat substantia nigra with filamentous inclusions and progressive neurodegeneration. PLoS One. 2017;12(1):e0169291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226781</ArticleId><ArticleId IdType="pubmed">28076378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsui S, Otomo A, Nozaki M, et al. Systemic over expression of SQSTM1/p62 accelerates disease onset in a SOD1H46R-expressing ALS mouse model. Mol Brain. 2018;11(1):30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975400</ArticleId><ArticleId IdType="pubmed">29843805</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibenhener ML, Zhao T, Yf D, et al. Behavioral effects of SQSTM1/p62 overexpression in mice: support for a mitochondrial role in depression and anxiety. Behav Brain Res. 2013;248:94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678260</ArticleId><ArticleId IdType="pubmed">23591541</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparicio R, Rana A, Walker DW, et al. Upregulation of the autophagy adaptor p62/SQSTM1 prolongs health and lifespan in middle-aged Drosophila. Cell Rep. 2019;28(4):1029&#x2013;1040.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688777</ArticleId><ArticleId IdType="pubmed">31340141</ArticleId></ArticleIdList></Reference><Reference><Citation>Du YF, Wooten MC, Gearing M, et al. Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease. Free Radic Biol Med. 2009;46(4):492&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684672</ArticleId><ArticleId IdType="pubmed">19071211</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>